Positron emission tomography imaging of prostate cancer.

Positron emission tomography imaging of prostate cancer.
复制标题

DOI:
10.1007/s00726-009-0394-9
复制
发表时间:
2010-06
期刊:
影响因子:
3.5
通讯作者:
Cai, Weibo
Cai, Weibo
中科院分区:
生物学3区
文献类型:
--
作者:
Hong, Hao;Zhang, Yin;Sun, Jiangtao;Cai, Weibo

文献摘要

参考文献

被引文献

相似文献

前列腺癌(PCa)是美国男性癌症死亡的第二大原因。正电子发射断层扫描(PET)是一种无创、灵敏、定量的成像技术,可以促进前列腺癌患者的个性化管理。 PCa PET 成像有两个关键需求:早期发现原发病灶和 PCa 骨转移(PCa 死亡的主要原因)的准确成像。由于临床上使用最广泛的 PET 示踪剂 18F-氟-2-脱氧-2-D-葡萄糖 (18F-FDG) 不能满足这些需求,因此针对 PCa 成像开发了多种 PET 示踪剂,其尺寸范围从小分子到完整抗体。在这篇综述中,我们将首先总结用于 PCa 成像的小分子 PET 示踪剂,该示踪剂可测量某些生物事件,如细胞膜代谢、脂肪酸合成和受体表达。接下来,我们将讨论放射性标记的氨基酸衍生物(例如蛋氨酸、亮氨酸、色氨酸和半胱氨酸类似物),它们主要基于 PCa 细胞氨基酸转运的增加。随后将详细介绍用于 PCa PET 成像的基于肽的示踪剂,主要基于与胃泌素释放肽受体结合的铃蟾肽及其衍生物。我们还将涵盖用于 PCa PET 成像的放射性标记抗体和抗体片段(例如双抗体和微型抗体),靶向整合素 αvβ3、EphA2、表皮生长因子受体或前列腺干细胞抗原。最后,我们将确定用于 PCa 成像的新型 PET 示踪剂的未来发展方向,这可能最终导致 PCa 患者的个性化管理。
Prostate cancer (PCa) is the second leading cause of cancer death among men in the United States. Positron emission tomography (PET), a non-invasive, sensitive, and quantitative imaging technique, can facilitate personalized management of PCa patients. There are two critical needs for PET imaging of PCa, early detection of primary lesions and accurate imaging of PCa bone metastasis, the predominant cause of death in PCa. Since the most widely used PET tracer in the clinic, 18F-fluoro-2-deoxy-2-D-glucose (18F-FDG), does not meet these needs, a wide variety of PET tracers have been developed for PCa imaging which span an enormous size range from small molecules to intact antibodies. In this review, we will first summarize small molecule-based PET tracers for PCa imaging, which measure certain biological events such as cell membrane metabolism, fatty acid synthesis, and receptor expression. Next, we will discuss radiolabeled amino acid derivatives (e.g. methionine, leucine, tryptophan, and cysteine analogs), which are primarily based on the increased amino acid transport of PCa cells. Peptide-based tracers for PET imaging of PCa, mostly based on the bombesin peptide and its derivatives which bind to the gastrin-releasing peptide receptor, will then be presented in detail. We will also cover radiolabeled antibodies and antibody fragments (e.g. diabodies and minibodies) for PET imaging of PCa, targeting integrin αvβ3, EphA2, the epidermal growth factor receptor, or the prostate stem cell antigen. Lastly, we will identify future directions for the development of novel PET tracers for PCa imaging, which may eventually lead to personalized management of PCa patients.
DOI: 10.1007/s00259-007-0503-5
发表时间: 2007-12-01
影响因子: 9.1
作者:
Cai, Weibo;Ebrahimnejad, Alireza;Chen, Xiaoyuan
通讯作者: Chen, Xiaoyuan
DOI: 10.1007/s00259-006-0361-6
发表时间: 2007-06-01
影响因子: 9.1
作者:
Cai, Weibo;Chen, Kai;Chen, Xiaoyuan
通讯作者: Chen, Xiaoyuan
DOI: 10.1073/pnas.93.2.749
发表时间: 1996-01-23
影响因子: 11.1
作者:
Carter, RE;Feldman, AR;Coyle, JT
通讯作者: Coyle, JT
DOI: 10.1007/s00259-006-0163-x
发表时间: 2007-02-01
影响因子: 9.1
作者:
Albrecht, Susanne;Buchegger, Franz;Miralbell, Raymond
通讯作者: Miralbell, Raymond
DOI: 10.1158/0008-5472.can-06-1480
发表时间: 2006-10-01
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Cai, Weibo;Wu, Yun;Chen, Xiaoyuan
通讯作者: Chen, Xiaoyuan